For research use only. Not for therapeutic Use.
Bacampicillin Hydrochloride（Cat No.:I003383）is an oral prodrug of ampicillin, designed to enhance ampicillin’s absorption in the gastrointestinal tract. Once ingested, it is converted to active ampicillin in the body, making it effective against a broad spectrum of bacterial infections, including respiratory, urinary tract, and gastrointestinal infections. By inhibiting bacterial cell wall synthesis, Bacampicillin Hydrochloride leads to cell lysis and bacterial death. Its improved bioavailability over standard ampicillin allows for efficient treatment with lower dosing frequency, enhancing patient compliance. It remains relevant in studies on antibiotic efficacy and prodrug development.
| Catalog Number | I003383 |
| CAS Number | 37661-08-8 |
| Molecular Formula | C21H28ClN3O7S |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | DMSO: ≥ 5.1 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydrochloride |
| InChI | InChI=1S/C21H27N3O7S.ClH/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12;/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25);1H/t11?,13-,14-,15+,18-;/m1./s1 |
| InChIKey | IWVTXAGTHUECPN-ANBBSHPLSA-N |
| SMILES | CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C.Cl |
| Reference | </br>1:Study of bacampicillin hydrochloride durability in tablets. Płotkowiak Z, Popielarz-Brzezińska M, Karolewska J, Mikołajczak A.Pharmazie. 1998 Sep;53(9):645-6. No abstract available. PMID: 9770215 </br>2:[Our experience in the field of therapy of infections in odontostomatology with bacampicillin hydrochloride]. Ferlito S.Clin Ter. 1987 Jul 15;122(1):9-12. Italian. No abstract available. PMID: 2973898 </br>3:In vitro-in vivo evaluation of bacampicillin hydrochloride from microcapsules of water-insoluble and an acid-soluble polymer. Sjöqvist R, Nyqvist H, Sjövall J, Westerlund D.J Microencapsul. 1985 Apr-Jun;2(2):123-36. PMID: 3880480 </br>4:Influence of epimer ratio on physicochemical properties of bacampicillin hydrochloride. Nyqvist H, Nicklasson M.Acta Pharm Suec. 1985;22(4):229-36. No abstract available. PMID: 4061108 </br>5:Structure-related variation in epimer ratio and solvent content of bacampicillin hydrochloride. Nyqvist H, Wadsten T.Acta Pharm Suec. 1985;22(4):215-28. No abstract available. PMID: 4061107 </br>6:Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolution. Sjövall J, Sjöqvist R, Huitfeldt B, Nyqvist H.J Pharm Sci. 1984 Feb;73(2):141-5. PMID: 6707871 </br>7:Rectal bioavailability of bacampicillin hydrochloride in man as determined by reversed-phase liquid chromatography. Sjövall J, Westerlund D, Alván G, Magni L, Nord CE, Sörstad J.Chemotherapy. 1984;30(3):137-47. PMID: 6734304 </br>8:[Bacampicillin hydrochloride in surgical wound infections in the oral cavity]. Nagano T, Abe K, Takenoshita K.Shikai Tenbo. 1984 Jan;63(1):203-10. Japanese. No abstract available. PMID: 6584996 </br>9:Bacampicillin hydrochloride: chemistry, pharmacology, and clinical use. Scheife RT, Neu HC.Pharmacotherapy. 1982 Nov-Dec;2(6):313-21. Review. PMID: 6762528 </br>10:Bacampicillin hydrochloride (Spectrobid). [No authors listed]Med Lett Drugs Ther. 1981 May 29;23(11):49-50. No abstract available. PMID: 7015096 |
